Onconetix Inc (ONCO)

Sep 26, 2025, 8:30 AM EDT - 2 months ago

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Sep 26, 2025, 8:15 AM EDT - 2 months ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Sep 22, 2025, 8:00 AM EDT - 2 months ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Jul 16, 2025, 8:17 AM EDT - 5 months ago

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jun 16, 2025, 8:22 AM EDT - 6 months ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 11, 2025, 11:30 AM EDT - 6 months ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

May 22, 2025, 4:50 PM EDT - 7 months ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 10:00 AM EDT - 7 months ago

Onco-Innovations Uplists to Cboe Canada

Mar 24, 2025, 8:45 AM EDT - 9 months ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 19, 2025, 8:00 AM EDT - 9 months ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Dec 12, 2024, 5:00 PM EST - 1 year ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS VRNA

Oct 3, 2024, 4:45 PM EDT - 1 year ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 1 year ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Sep 27, 2024, 2:41 PM EDT - 1 year ago

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 20, 2024, 11:45 AM EDT - 1 year ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Feb 13, 2024, 6:00 AM EST - 1 year ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Dec 19, 2023, 7:00 AM EST - 2 years ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 18, 2023, 7:00 AM EST - 2 years ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Issues Letter to Shareholders

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Aug 28, 2023, 4:30 PM EDT - 2 years ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 3, 2023, 1:02 PM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 21, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 14, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

May 12, 2023, 6:32 PM EDT - 2 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 12:15 PM EDT - 2 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Apr 26, 2023, 3:44 PM EDT - 2 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Mar 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Feb 6, 2023, 10:15 AM EST - 3 years ago

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Feb 1, 2023, 9:15 AM EST - 3 years ago

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Jan 17, 2023, 8:30 AM EST - 3 years ago

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

Jan 9, 2023, 8:30 AM EST - 3 years ago

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Mon, 12 Dec 2022 08:30:00 -0500 - 3 years ago

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both